echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Hemophilia A gene therapy shows promise in phase 3 clinical trial

    Hemophilia A gene therapy shows promise in phase 3 clinical trial

    • Last Update: 2022-04-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    New England Journal of Medicine (2022)


    Research by an international team of researchers has found more evidence that a new gene therapy for hemophilia A may help some people, in their paper published in the New England Journal of Medicine by a group describing the characteristics of clinical trials and provide data on the effectiveness of the treatment


    Hemophilia A is a genetic disorder that affects the production of a protein called factor 8, and people with the disease experience blood clotting problems


    Currently, hemophilia A patients are treated with factor VIII infusions, and while it is effective in allowing patients to lead normal lives, treatment is considered burdensome and expensive


    In the clinical trial, 132 otherwise healthy patients with hemophilia A received a one-time injection of valoccogene roxaparvovec and were monitored for more than a year


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.